Text messaging
BehavioralSubjects contacted 3 times weekly via text messaging for the study period.
NCT Number: NCT03082703
This randomized study aims at examining the impact of text messaging in the management of non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH), a disease frequently associated with obesity and varying components of metabolic syndrome including diabetes mellitus, hypertension, and dyslipidemia. With rising incidence of obesity in the US, NAFLD and NASH are rapidly increasing with currently the second etiology for liver transplantation in the US. The objectives of this protocol are to a) prospectively enroll patients with NAFLD and NASH; b) randomize them to receiving text messaging to help manage obesity and other components od metabolic syndrome in addition to standard clinical care or receiving only standard clinical care; and c) follow up these patients at the end of 3 months period for weight loss, blood pressure control, HBA1c, and liver enzymes. The immediate aim of this protocol is to develop the pilot data on the usefulness of text messaging in the management of NAFLD and NASH. The long-term goals of this research are to establish text messaging as a beneficial intervention in the management of weight loss and control of risk factors of NAFLD and improve outcomes of these patients with NAFLD and NASH.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Not applicable
Patients will be recruited primarily from the outpatient Liver Kirklin Clinic setting.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Subjects contacted 3 times weekly via text messaging for the study period.
Time frame: 6 months
Ashwani Singal,MD
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07241195
Digestive System Diseases, Fatty Liver
Hangzhou, Zhejiang, China
View Trial DetailsNCT06297434
Digestive System Diseases, Fatty Liver
Busan, South Korea
View Trial DetailsNCT02520609
Digestive System Diseases, Fatty Liver
Bethesda, Maryland, United States
View Trial DetailsNCT07730905
Blood-Borne Infections, Chronic Disease
Foshan, Guangdong, China
View Trial Details